# Effectiveness and Safety of COVID-19 Vaccine in Patients With IBD Treated With Immunomodulatory or Biological Drugs (ESCAPE-IBD)

> **NCT04769258** · — · UNKNOWN · sponsor: **Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)** · enrollment: 1380 (estimated)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **BIOLOGICAL:** Pfizer Comirnaty vaccine

## Key facts

- **NCT ID:** NCT04769258
- **Lead sponsor:** Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 1380 (ESTIMATED)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04769258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04769258, "Effectiveness and Safety of COVID-19 Vaccine in Patients With IBD Treated With Immunomodulatory or Biological Drugs (ESCAPE-IBD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04769258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*